GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reviva Pharmaceuticals Holdings Inc (NAS:RVPH) » Definitions » ROA %

Reviva Pharmaceuticals Holdings (Reviva Pharmaceuticals Holdings) ROA % : -267.45% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Reviva Pharmaceuticals Holdings ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Reviva Pharmaceuticals Holdings's annualized Net Income for the quarter that ended in Dec. 2023 was $-38.90 Mil. Reviva Pharmaceuticals Holdings's average Total Assets over the quarter that ended in Dec. 2023 was $14.54 Mil. Therefore, Reviva Pharmaceuticals Holdings's annualized ROA % for the quarter that ended in Dec. 2023 was -267.45%.

The historical rank and industry rank for Reviva Pharmaceuticals Holdings's ROA % or its related term are showing as below:

RVPH' s ROA % Range Over the Past 10 Years
Min: -28233.33   Med: -112.31   Max: -42.43
Current: -269.82

During the past 5 years, Reviva Pharmaceuticals Holdings's highest ROA % was -42.43%. The lowest was -28233.33%. And the median was -112.31%.

RVPH's ROA % is ranked worse than
95.24% of 1555 companies
in the Biotechnology industry
Industry Median: -35.15 vs RVPH: -269.82

Reviva Pharmaceuticals Holdings ROA % Historical Data

The historical data trend for Reviva Pharmaceuticals Holdings's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reviva Pharmaceuticals Holdings ROA % Chart

Reviva Pharmaceuticals Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
-28,233.33 -86.32 -42.43 -112.31 -184.22

Reviva Pharmaceuticals Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -224.18 -165.98 -402.30 -487.13 -267.45

Competitive Comparison of Reviva Pharmaceuticals Holdings's ROA %

For the Biotechnology subindustry, Reviva Pharmaceuticals Holdings's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reviva Pharmaceuticals Holdings's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reviva Pharmaceuticals Holdings's ROA % distribution charts can be found below:

* The bar in red indicates where Reviva Pharmaceuticals Holdings's ROA % falls into.



Reviva Pharmaceuticals Holdings ROA % Calculation

Reviva Pharmaceuticals Holdings's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-39.261/( (18.924+23.7)/ 2 )
=-39.261/21.312
=-184.22 %

Reviva Pharmaceuticals Holdings's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-38.896/( (5.387+23.7)/ 2 )
=-38.896/14.5435
=-267.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Reviva Pharmaceuticals Holdings  (NAS:RVPH) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-38.896/14.5435
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-38.896 / 0)*(0 / 14.5435)
=Net Margin %*Asset Turnover
=N/A %*0
=-267.45 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Reviva Pharmaceuticals Holdings ROA % Related Terms

Thank you for viewing the detailed overview of Reviva Pharmaceuticals Holdings's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Reviva Pharmaceuticals Holdings (Reviva Pharmaceuticals Holdings) Business Description

Traded in Other Exchanges
N/A
Address
19925 Stevens Creek Boulevard, Suite 100, Cupertino, CA, USA, 95014
Reviva Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, respiratory, and metabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, 1) Brilaroxazine (RP5063) which is in clinical development and is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and 2) RP1208.
Executives
Purav Patel director 19925 STEVENS CREEK BLVD., SUITE 100, CUPERTINO CA 95014
Narayan Parbhu officer: Chief Financial Officer 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA 95014
Beta Operators Fund, L.p. 10 percent owner 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Vedanta Associates, L.p. 10 percent owner 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Vedanta Partners, Llc 10 percent owner 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Vedanta Associates-r, Lp 10 percent owner 250 WEST 55TH STREET, STE 13D, NEW YORK NY 10019
Parag Saxena director, 10 percent owner 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Rahul Nayar 10 percent owner 250 WEST 55TH STREET, NEW YORK NY 10019
Tenzing Llc director, 10 percent owner 250 WEST 55TH STREET, NEW YORK NY 10019
Laxminarayan Bhat director, 10 percent owner, officer: President and CEO 19925 STEVENS CREEK BLVD., SUITE 100, CUPERTINO CA 95014
Leslie D. Funtleyder director C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Marc Cantillon officer: Chief Medical Officer 19925 STEVENS CREEK BLVD., SUITE 100, CUPPERTINO CA 95014
Richard A Margolin director 19925 STEVENS CREEK BLVD, SUITE 100, CUPPERTINO CA 95014
Glazer Capital, Llc 10 percent owner 250 WEST 55TH STREET, SUITE 30A, NEW YORK NY 10019
Paul J Glazer 10 percent owner 250 WEST 55TH ST, SUITE 30A, NEW YORK NY 10019